CALGB 40603 – comparison 2 (with bevacizumab).

Study characteristics
Methods	See details in CALGB 40603
Participants	See details in CALGB 40603
Interventions	4‐arm study that has been split into 2 treatment comparisons where possible. Treatment comparison 2 includes: Arm 1 (listed as arm 4 in the trial publication): paclitaxel 80 mg/m2 weekly + carboplatin AUC6, 3 weekly for 12 weeks followed by doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles and bevacizumab 10 mg/kg every 2 weeks for 9 cycles Arm 2 (listed as arm 2 in the trial publication): paclitaxel 80 mg/m2 weekly for 12 weeks followed by doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles and bevacizumab 10 mg/kg every 2 weeks for 9 cycles
Outcomes	See details in CALGB 40603
Notes	See details in CALGB 40603